Skip to content
DataLookout
Menu

NCT06545747

Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words
    • Enrollment closed, study ongoing
    • Site details revised
  2. Notable Eligibility criteria expanded, about 9 wordsv3
  3. Notable Enrollment target: 304 to 490v2 Show 4 more changesShow less
    • Primary and study completion dates: Dec 31, 2027 to Jul 31, 2028
    • Start date: Jan 1, 2024 to Aug 1, 2024
    • Primary endpoints: 1 to 2
    • Secondary endpoints: 5 to 4
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

treatment-related G2+ respiratory toxicity
Timeframe: Recorded from the enrollment to 1 year after the completion of hypo-RT or 3 months after the completion of consolidative immunotherapy
progression-free survival rate
Timeframe: 2-year

Secondary (4)

local control rate
overall survival rate
patient reported outcome assessed by QLQ-C30
patient reported outcome

Arms and interventions

MRI-based hypo-RTExperimental

Patients will receive split-course hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. The experimental arm will undergo adaptive dose-painting hypo-RT based on DCE-MRI.

CT-based hypo-RTActive comparator

Patients will receive split-course hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. The control arm will undergo hypo-RT based on CT.

Radiation: DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT

Drugs: Concurrent chemotherapy, Consolidative immunotherapy

Sites

1 site in 1 country

  • Sun Yat-sen University Cancer CenterGuangzhou, China